Diagnoly has launched its fetal ultrasound AI tool Fetoly on iOS, extending access via iPad without additional hardware or system upgrades.

Diagnoly’s update centres on usability rather than new clinical evidence, marking a product rollout rather than a research or regulatory milestone. The company said the iOS version allows clinicians to connect the software directly to existing ultrasound systems and use it during routine scans.

Camille Dupont, chief technical officer at Diagnoly, said: “Bringing Fetoly to iOS is an important step in our mission to make advanced fetal ultrasound AI available in routine clinical practice worldwide. Our objective is simple: provide healthcare professionals a second set of expert eyes in real- time, directly during the examination.”

The application runs locally on the device rather than via cloud processing, which the company claims supports data security and avoids workflow disruption. Clinicians can use the system on an iPad without modifying existing imaging infrastructure, reflecting a growing focus in digital health on software overlays rather than new hardware.

Fetoly is designed to analyse the full ultrasound video stream in real time during fetal examinations. According to Diagnoly, it assesses whether required anatomical structures have been visualised and flags potential abnormalities through automated measurements. The clinician remains responsible for interpretation and diagnosis.

The latest version (2026.02.25) includes updates to processing speed and anatomical detection. It also introduces automated ratios aimed at supporting identification of ventriculomegaly, corpus callosum abnormalities and total anomalous pulmonary venous return. These additions reflect ongoing efforts to embed more quantitative assessment into routine scans.

Fetal ultrasound is widely recognised as operator dependent, with outcomes influenced by experience and clinical setting. Tools such as Fetoly are positioned as decision-support systems intended to reduce variability and improve consistency across examinations. However, no independent performance data or peer-reviewed validation results were disclosed in the announcement.

Diagnoly also referenced a recent collaboration with GE HealthCare, suggesting compatibility with established imaging platforms. The integration approach aligns with broader industry trends favouring interoperability and incremental adoption of AI in clinical workflows.

The company said uptake has expanded across more than 20 countries, though it did not provide detailed deployment figures or breakdowns by region. Claims of user satisfaction and adoption were included but not substantiated with metrics.

The iOS launch supports Diagnoly’s strategy to scale access through mobile platforms, particularly in settings where upgrading imaging systems may be cost-prohibitive. Clinicians can download the application via standard app distribution channels or request a demonstration directly from the company.

While the update highlights continued commercial expansion, the absence of new clinical data suggests the development is primarily a distribution milestone. Ongoing evaluation of real-world performance and clinical impact will be key to determining the technology’s role in prenatal care.